ADUS

NEUTRALM&A

Addus HomeCare Corporation

2026-10-28

Price

$122.18

+0.78%

This is the 2026-10-28 snapshot — the signals and analysis for ADUS as of this single trading day.

View full ADUS research hub →

Score9.5Priority

Signals4/8 DNA2/13 Act · 2/4 Risk

SentimentNEUTRALScore: 8

Volume1.7xvs 20d avg

Analysis

Addus HomeCare (ADUS) is exhibiting High-Conviction Price Discovery, driven by institutional absorption of its $275 million acquisition of AccentCare's personal care division. The combination of PERFECT_STACK and QUIET_ACCUMULATION signals confirms that buyers are actively positioning ahead of its upcoming Q3 earnings print. Supported by a RISK_ON macro regime with exceptionally tight credit spreads, the market is confidently rewarding this M&A-driven growth story, viewing the debt-financed expansion as highly accretive rather than a balance sheet risk.

Fired Signals

ALPHA MALESTEADY CLIMBGOLDEN CROSSPERFECT STACKQUIET ACCUMULATIONINSIDE OUTDISTRIBUTIONCHURNING

Key Takeaways

Actionable Thesis: ADUS is demonstrating relative strength (+9.4% vs SPY) and urgent volume (1.7x average), making it a prime momentum candidate heading into earnings.
Key Risk: Lingering concerns over slowing organic growth in the legacy home health segment, which prompted a prior BofA downgrade, could resurface.
What to Watch: Monitor the upcoming Q3 earnings call for updates on the AccentCare integration timeline and any shifts in Medicaid managed care reimbursement rates.

← Back to 2026-10-28 View Full ADUS History →Yahoo Finance &nearr;